These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 31367043)

  • 1. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
    Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
    Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights into the function of CD24: A driving force in cancer.
    Altevogt P; Sammar M; Hüser L; Kristiansen G
    Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
    Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
    J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
    Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
    Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint CD24 function on tumor and immunotherapy.
    Huang S; Zhang X; Wei Y; Xiao Y
    Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 11. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
    Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
    J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses.
    Zhang W; Zeng Y; Xiao Q; Wu Y; Liu J; Wang H; Luo Y; Zhan J; Liao N; Cai Y
    Nat Commun; 2024 Jul; 15(1):5670. PubMed ID: 38971872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
    Chen C; Zhang L; Ruan Z
    Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
    Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
    J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
    Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
    Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
    Yin SS; Gao FH
    Front Immunol; 2020; 11():1324. PubMed ID: 32765491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy.
    Yang Y; Wu H; Yang Y; Kang Y; He R; Zhou B; Guo H; Zhang J; Li J; Ge C; Wang T
    Mol Ther Oncolytics; 2023 Dec; 31():100747. PubMed ID: 38046893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.